|Early Drug Development in cooperation with the Pharmaceutical Industry|
Epitome Pharmaceuticals identifies, develops and licenses promising medications. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data.
Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.
Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.
October 2011 US Patent Office grants patent for Epitome Pharmaceuticals' Lip balm formulation for cold sore prevention.
October 2006 US FDA approves Veregen®, the first botanical approved under new regulations.
|Veregen® is a registered trademark of MediGene AG.|